What’s the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
Investors are always on the lookout for the next revolutionary technology or product. In recent times, this has…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
An updated edition of the June 27, 2025, article. Genomics encompasses the study of a complete set of…